While this specialty pharma stock has not been outperforming the broader market year to date, there are several reasons to believe that will change – including recent FDA approval of its first and only treatment for a rare eye disease. CLICK HERE.
Approval For Its Rare Eye Disease Treatment Make This Pharma Stock Worth A Look
- by Ashley Hayes
- March 18, 2020April 17, 2021